Pfizer (PFE) traded at $26.59, down $0.03 or 0.09%, as investors weighed a meaningful late-stage oncology win against the drag from fading COVID-era products and looming patent expirations. The move came on a rough session for the broader group, with the healthcare sector down 2.16%, keeping even positive biotech headlines from translating into a clean risk-on rally.
The center of attention was a pivotal bladder cancer readout tied to Pfizer’s oncology rebuild. A strong Phase 3 outcome can matter more than a small daily price tick, because it speaks to future revenue mix at a time when Pfizer is working through a post-pandemic reset and a widening loss-of-exclusivity schedule.
Phase 3 bladder cancer data adds weight to the oncology pivot
Pfizer and partner Astellas reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle-invasive bladder cancer. In the EV-304 (KEYNOTE-B15) study, the combination showed a 47% reduction in the risk of tumor recurrence, progression, or death versus standard chemotherapy, along with a 35% reduction in the risk of death. The companies also pointed to a consistent safety profile for the regimen and indicated regulatory filings are expected based on these results.
For investors tracking Pfizer’s long-term direction, this result lands directly inside the company’s stated emphasis on oncology as a durable growth engine alongside vaccines and other specialty medicines. Muscle-invasive bladder cancer remains a high-need setting, and outcomes that compare favorably to chemotherapy can shift clinical practice over time, expanding the commercial opportunity if approvals follow established pathways. Background context on bladder cancer and treatment approaches is available through the National Cancer Institute’s bladder cancer overview.
Oncology momentum builds while competition stays intense
Pfizer’s oncology push is not occurring in a quiet market. The company is scaling a broader, oncology-focused portfolio in an arena crowded with deep-pocketed competitors such as Merck, Bristol Myers Squibb, and Roche. That raises the execution bar: strong data can strengthen the investment narrative, but any regulatory delays, commercial frictions, or competitive setbacks can have an outsized impact when markets are already sensitive to the post-COVID revenue transition.
Pfizer’s pipeline is described as extensive, with 102 candidates in development including 32 Phase 3 programs, reinforcing the view that management is attempting to rebuild breadth after pandemic-era products peaked. Positive late-stage data like EV-304 can become a key reference point for how investors calibrate Pfizer’s oncology thesis, especially as the company aims to offset both patent losses and the step-down in COVID-related demand.
Analyst tone turns cautiously constructive
On the Street, positioning has leaned cautious rather than euphoric. Argus upgraded Pfizer to Buy, pointing to potential from its GLP-1 and oncology programs even as near-term revenue uncertainty persists. At the same time, price targets cited in the analyst mix clustered around $24 to $28, a range that suggests a neutral-to-measured stance close to recent trading levels rather than a broad expectation of immediate upside.
Valuation has also drawn widely different interpretations. Estimates shared in your notes put fair value in a broad band from $30.62 to $64.53, underlining how much of Pfizer’s medium-term story depends on confidence in execution, pipeline conversion, and the pace of COVID product normalization.
Financial performance shows resilience with visible pressure points
Pfizer’s latest quarter offered a snapshot of resilience inside the core franchise even as COVID products continued to unwind. The company reported Q4 2025 adjusted earnings per share of $0.66 versus a consensus estimate of $0.57, with earnings up 5% year over year supported by cost savings and gross margin expansion. Revenue was $17.6 billion, down 1% on a reported basis and down 3% operationally, driven by a 40% operational decline in COVID-19 product revenues.
Total revenue still exceeded expectations of $16.84 billion, and non-COVID products rose 9% operationally in the quarter, helped by products including Eliquis, the Prevnar family, the Vyndaqel family, oncology biosimilars and Abrysvo. International revenue declined 4% operationally to $8.44 billion, while U.S. revenue declined 1% to $9.1 billion.
Expense trends reflected a company balancing productivity efforts with pipeline investment. Adjusted SI&A expenses declined 5% operationally to $4.08 billion, while adjusted R&D rose 4% to $3.12 billion, reflecting pipeline optimization and higher spending tied to oncology and obesity development.
Business mix shows the post-COVID shift in real numbers
Pfizer reports revenue across Primary Care, Specialty Care, and Oncology. In Q4, Primary Care sales declined 13% operationally to $7.94 billion. Specialty Care rose to $4.77 billion, up 6%. Oncology climbed to $4.44 billion, up 8%, aligning with the strategic message that oncology is expected to take a larger role in the next chapter.
Within Primary Care, Eliquis alliance revenue and direct sales rose 8% to $2.02 billion, while the Prevnar family rose 8% to $1.71 billion. COVID product performance highlighted the headwind: Comirnaty revenue was $2.27 billion, down 35% year over year, while Paxlovid was $218 million, down 70%. Nurtec contributed $405 million, up 3%. Pfizer’s RSV vaccine Abrysvo delivered $481 million, up 136% operationally, with uptake influenced by recommendation dynamics.
Specialty Care was led by the Vyndaqel family at $1.69 billion, up 7%. Xeljanz declined to $324 million, down 8%, and Enbrel revenue was $180 million, down 5%. Cibinqo produced $78 million, up 22%.
In Oncology, Ibrance revenue was $1.04 billion, down 7%. Among Seagen-linked assets, Adcetris delivered $220 million, down 23%, while Padcev rose 15% to $508 million. Xtandi alliance revenue came in at $592 million, up 5%. Lorbrena rose 45% to $282 million. Braftovi and Mektovi combined for $197 million, up 16%. Oncology biosimilars advanced to $369 million, up 76%.
Guidance frames the next year as a transition period
For 2026, Pfizer guided total revenue to $59.5 billion to $62.5 billion, below 2025 revenue of $62.6 billion, reflecting lower COVID revenue and the expected impact of patent losses. The loss-of-exclusivity cliff was estimated to reduce revenue by about $1.5 billion in 2026. COVID sales were projected at roughly $5 billion for 2026 versus about $6.7 billion in 2025. Excluding COVID products and the LOE impact, Pfizer projected 4% operational revenue growth.
Adjusted EPS guidance for 2026 was $2.80 to $3.00, down from $3.22 in 2025, with the outlook reflecting lower COVID revenue, higher taxes, and deal-related dilution noted in your materials. In that context, pipeline milestones can act as the most credible counterweight, particularly in oncology where large indications can move the needle.
Insider filings show tax-driven activity with a notable award
Insiders reported 5 transactions totaling $471,458.14 from late January through late February 2026. Activity was dominated by 4 tax payment transactions totaling $392,262.13, representing over 83% of the total value. The largest single tax payment was $340,732.28 by Christoffel Boshoff on January 30, 2026. Jennifer B. Damico (SVP & Controller) reported two tax payment transactions totaling $29,448.89.
Award activity included a single grant to Albert Bourla (Chairman & CEO) of 2,883 phantom stock units valued at $79,196.01. The average transaction value across all filings was $94,291.63, with tax payments averaging $98,065.53 and the award at $79,196.01. The reported activity came from senior executives, with no director or non-officer transactions in that period.
Performance takeaway for investors tracking the next catalyst
With PFE at $26.59 and the broader healthcare group under pressure, the day’s small move masked a larger set of crosscurrents. On one side, Pfizer is managing a visible step-down in COVID products and an estimated $1.5 billion revenue hit tied to patent losses in 2026. On the other, the company continues to deliver earnings resilience, expand oncology revenue, and add late-stage proof points like EV-304 that support the thesis of a rebalanced product mix.
That leaves the stock trading as a transition story: near-term uncertainty still matters, but Phase 3 oncology wins, a deep pipeline, and continued execution in large franchises are the levers that can reshape expectations over time, especially as regulators review the bladder cancer filing and investors look for durable sources of growth beyond the pandemic cycle.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
